Drug Profile
Research programme: transforming growth factor beta receptor kinase inhibitors - Bristol-Myers Squibb/Rigel
Alternative Names: TGF beta receptor kinase inhibitors - Bristol-Myers Squibb/RigelLatest Information Update: 28 Mar 2019
Price :
$50
*
At a glance
- Originator Rigel Pharmaceuticals
- Developer Bristol-Myers Squibb; Rigel Pharmaceuticals
- Class Small molecules
- Mechanism of Action TGF-beta superfamily protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer